文献速递特殊人群用药治疗药物监测与药物基因组学

精神药物在妊娠期与哺乳期的浓度变化及子代早期发育

Psychotropic medication in pregnancy and lactation and early development of exposed children.
PubMed 文献 · Br J Clin Pharmacol · 2022-10-03

本研究在60名母亲的自然样本中,于妊娠期和哺乳期不同时间点检测血清与母乳中精神药物浓度,并随访子代出生后12个月发育。结果显示多种药物血清浓度从孕早期到孕中期下降,母乳中药物浓度与剂量比值因药而异,暴露与未暴露新生儿出生结局及12个月发育无显著差异。

要点

  • 阿米替林、度洛西汀、艾司西酞普兰、喹硫平、舍曲林血清浓度从孕早期到孕中期下降。
  • 文拉法辛和拉莫三嗪母乳浓度/剂量比值高,喹硫平和氯米帕明低。
  • 宫内暴露与未暴露新生儿出生结局及12个月发育无显著差异。

核心结论

  • 围产期精神药物需权衡风险与获益,治疗药物监测可指导妊娠期和哺乳期以最低有效剂量优化用药。

研究设计与样本

  • 自然样本研究,纳入60名母亲,在妊娠期和哺乳期不同时间点检测血清与母乳药物浓度,并观察子代出生后12个月发育。

主要发现

  • 阿米替林、度洛西汀、艾司西酞普兰、喹硫平、舍曲林血清浓度从孕早期到孕中期下降。
  • 西酞普兰孕期浓度较稳定,舍曲林从孕中期到孕三级浓度再次升高。
  • 文拉法辛和拉莫三嗪母乳浓度/剂量比值高,喹硫平和氯米帕明低;氯米帕明和喹硫平母乳/血清渗透比低。
  • 宫内暴露与未暴露新生儿出生结局无显著差异,子代12个月内发育无显著差异。

临床怎么用

  • 围产期使用精神药物应权衡风险与获益。
  • 连续治疗药物监测可帮助临床医生监测妊娠相关药代动力学变化引起的药物浓度波动。
  • 治疗药物监测可用于妊娠期和哺乳期以最低有效剂量优化用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is still limited knowledge about alterations of blood concentrations of psychotropic drugs during pregnancy, the transfer of psychotropic drugs into breastmilk and the effects on exposed children. We investigated changes in concentrations of psychopharmacological medication during pregnancy and lactation in serum and breastmilk at different time points in a naturalistic sample of 60 mothers and observed the development of the exposed children in the first 12 months. We found a decrease in serum concentrations from the first to the second trimester of amitriptyline, duloxetine, escitalopram, quetiapine and sertraline. Citalopram stayed rather stable during pregnancy, sertraline levels interestingly increased again from the second to the third trimester. High concentration-by-dose ratios in breastmilk were found for venlafaxine as well as lamotrigine, low for quetiapine and clomipramine. Similarly, clomipramine and quetiapine showed low milk/serum-penetration ratios. Regarding the birth outcome measures in children, we found no significant differences between in utero exposed compared to nonexposed newborns. There were no significant differences in the development in the first 12 months. Psychotropic medication in the peripartum needs a balancing of risks and benefits and a continuous therapeutic drug monitoring can be a guidance for clinicians to monitor drug alteration patterns, which are likely to occur due to physiological pregnancy-associated changes in pharmacokinetics. Accordingly, therapeutic drug monitoring can optimize a medication in pregnancy and lactation with the lowest effective dose.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Leutritz AL, van Braam L, Preis K, et al. Psychotropic medication in pregnancy and lactation and early development of exposed children. Br J Clin Pharmacol. 2022. PMID: 36103361. doi:10.1111/bcp.15533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。